John P. Hamill's most recent trade in Aprea Therapeutics Inc was a trade of 50 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on Oct. 11, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 2.46 per share. | 11 Oct 2024 | 50 | 19,368 (0%) | 0% | 2.5 | 123 | Common Stock |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 2.61 per share. | 10 Oct 2024 | 450 | 19,318 (0%) | 0% | 2.6 | 1,175 | Common Stock |
Aprea Therapeutics Inc | Hamill P. John | SrVP/CFO/Prin Fin & Acct Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 13,460 | 13,460 | - | - | Stock Options (Right to Buy) | |
Aprea Therapeutics Inc | Hamill P. John | SrVP/CFO/Prin Fin & Acct Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 3,365 | 18,868 (0%) | 0% | 0 | Common Stock | |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 13 Mar 2024 | 1,010 | 15,503 (0%) | 0% | 7.3 | 7,363 | Common Stock |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 505 | 505 | - | - | Tranche B Warrant | |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 505 | 505 | - | - | Tranche A Warrant | |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Grant, award, or other acquisition of securities at price $ 5.25 per share. | 27 Feb 2023 | 1,000 | 14,493 (0%) | 0% | 5.3 | 5,250 | Common Stock |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin. Fin&Acctg. Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 539,758 | 539,758 | - | - | Employee Stock Option (Right to Buy) | |
Aprea Therapeutics Inc | John P. Hamill | SrVP/CFO/Prin. Fin&Acctg. Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 269,879 | 269,879 (1%) | 1% | 0 | Common Stock | |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 26 Jul 2022 | 3,000 | 72,800 (0%) | 0% | 0.4 | 1,100 | Common Stock |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 99,600 | 99,600 | - | - | Employee Stock Option (Right to Buy) | |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 66,300 | 69,800 (0%) | 0% | 0 | Common Stock | |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Purchase of securities on an exchange or from another person at price $ 2.07 per share. | 16 Apr 2021 | 1,000 | 3,500 (0%) | 0% | 2.1 | 2,067 | Common Stock |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 25 Mar 2021 | 1,500 | 1,500 | - | - | Common Stock Warrants | |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Purchase of securities on an exchange or from another person at price $ 3.25 per share. | 25 Mar 2021 | 1,500 | 2,500 (0%) | 0% | 3.3 | 4,875 | Common Stock |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Purchase of securities on an exchange or from another person at price $ 5.27 per share. | 07 Oct 2020 | 1,000 | 1,000 (0%) | 0% | 5.3 | 5,270 | Common Stock |
Windtree Therapeutics Inc | John P. Hamill | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 211,000 | 211,000 | - | - | Non-Qualified Stock Option (Right to Buy) |